Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD) Phase 2 study results to be presented at The Liver Meeting® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants...

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...

Global Metabolic Panel Testing Market to Grow with a CAGR of ~7% During 2022-2031; Market Growth to be Propelled by Increasing Prevalence of Chronic Diseases, Surge in the Geriatric Population, and Advancement in Healthcare Sector New York, July 25, 2022 (GLOBE NEWSWIRE) -- It was noticed that around 2 million people globally pass away from the liver disease each year, with 1 million of those fatalities coming from cirrhosis...

Human Liver Models Market Size ($508.26Mn by 2028) Lead by Liver-on-a-Chip Type (11.7% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com New York, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The new research study on the Human Liver Models Market Size and Forecast to 2028 by Type (Liver Organoids, Liver-on-a-Chip, 2D Models, 3D Bioprinting,...